GBT Global Blood Therapeutics Inc

Global Blood Therapeutics Inc is a clinical-stage biopharmaceutical company in the United States. Its major focus lies on developing therapeutics for the treatment of blood-based disorders such as red blood cell sickling.

$26.96  -0.14 (-0.52%)
As of 09/21/2021 15:59:57 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/12/2015
Outstanding shares:  62,412,062
Average volume:  1,026,237
Market cap:   $1,644,557,834
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    37890U108
ISIN:        US37890U1088
Sedol:      BZ05388
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy